The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
The company also raised Rs 270 crore investment from Temasek in 2019
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
The site consists of five fermentation "mini-factories" capable of concurrently producing our more than 13 currently scaled and future bio-fermented products
Ind-Ra maintains a neutral outlook for healthcare in FY23
It is one of the 15 medical device manufacturers approved under the government’s PLI scheme
The expansion makes Exothera one of the largest viral vector facilities in Europe
Subscribe To Our Newsletter & Stay Updated
